A prospective study on the prevalence of at‐risk <scp>MASH</scp> in patients with type 2 diabetes mellitus in the United States

Abstract

Among adults aged ≥50 years with T2DM, the prevalence of MASLD, at-risk MASH and cirrhosis is high, posing a significant risk for liver-related morbidity and mortality. Approximately 14% of patients with T2DM may be candidates for pharmacologic therapies specific to MASH-related fibrosis.